| 284.49 1.03 (0.36%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 348.06 | 1-year : | 406.53 |
| Resists | First : | 298 | Second : | 348.06 |
| Pivot price | 283.35  |
|||
| Supports | First : | 277.82 |
Second : | 265.35 |
| MAs | MA(5) : | 283.32 |
MA(20) : | 281.48 |
| MA(100) : | 250 |
MA(250) : | 213.96 |
|
| MACD | MACD : | 4.6 |
Signal : | 5.8 |
| %K %D | K(14,3) : | 55 |
D(3) : | 52.9 |
| RSI | RSI(14): 55.5 |
|||
| 52-week | High : | 299.98 | Low : | 119.76 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ MDGL ] has closed below upper band by 45.4%. Bollinger Bands are 45.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 290.35 - 291.52 | 291.52 - 292.72 |
| Low: | 273.84 - 275.02 | 275.02 - 276.23 |
| Close: | 282.52 - 284.61 | 284.61 - 286.76 |
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Fri, 26 Jul 2024
State Board of Administration of Florida Retirement System Decreases Stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - Defense World
Thu, 25 Jul 2024
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Sold by Sei Investments Co. - Defense World
Wed, 24 Jul 2024
Madrigal Pharmaceuticals to Release Second-Quarter 2024 Financial Results and Host Webcast on August 7, 2024 - StockTitan
Wed, 08 May 2024
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2024 Earnings Call Transcript - Yahoo Finance
Tue, 26 Mar 2024
Here's 1 Huge New Reason to Buy Madrigal Pharmaceuticals Stock - The Motley Fool
Fri, 15 Mar 2024
Madrigal Pharmaceuticals Stock Surges After FDA Approves Liver Disease Treatment - The Wall Street Journal
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 21 (M) |
| Shares Float | 13 (M) |
| Held by Insiders | 15.1 (%) |
| Held by Institutions | 99.5 (%) |
| Shares Short | 4,080 (K) |
| Shares Short P.Month | 5,230 (K) |
| EPS | -23.15 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 41.13 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -40.2 % |
| Return on Equity (ttm) | -88.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -21.29 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -389 (M) |
| Levered Free Cash Flow | -230 (M) |
| PE Ratio | -12.29 |
| PEG Ratio | 0 |
| Price to Book value | 6.91 |
| Price to Sales | 0 |
| Price to Cash Flow | -15.58 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|